
U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 3 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 24-24405-01	Docket or Reference No.: 030-18606	
	Amendment No. 30		

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 17065 S. 71 Hwy., Belton, Missouri, 64012.
- 11. The Radiation Safety Officer (RSO) for this license is Joshua R. McIlvain, MS.
- 12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,e	etc.) Material and Use
Michael E. Farber, M.D.	10 CFR 35.100,10 CFR 200,10 CFR 300 (limited to the oral administration of sodium iodide
	I-131 in quantities of 33 millicuries or less)
Barry A. Gubin, M.D.	10 CFR 35.100,10 CFR 200,10 CFR 300 (limited to the oral administration of sodium iodide
	I-131 in quantities of 33 millicuries or less)
Ryan M. Hegg, M.D.	10 CFR 35.100,10 CFR 200,10 CFR 300 (limited to the oral administration of sodium iodide
	I-131 and parenteral administration of any beta emitter or photon-emitting radionuclide with a
	photon energy less than 150 keV)
Jared L. Hodgson, M.D.	10 CFR 35.100,10 CFR 200,10 CFR 300 (limited to the oral administration of sodium iodide
	I-131 in quantities of 33 millicuries or less)
Graham K. Lee, M.D.	10 CFR 35.100,10 CFR 35.200
Kevin L. Litwin, M.D.	10 CFR 35.100,10 CFR 35.200

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 3 OF 3 PAGES			
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 24-24405-01 Amendment No. 30	Docket or Reference No.: 030-18606				
representations, and procedures contained those procedures that are required to be slicensee's ability to make changes to the Commission's regulations shall govern uncorrespondence are more restrictive than A. Application dated March 18, 2021 (MI	representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.					
	FOR	THE U.S. NUCLEAR REGULATO	RY COMMISSION			
Date: September 20, 2021		Cassandra F. Frazier Region 3				